Detection and quantification of CD8+ T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-γ-elispot assay

International Journal of Cancer

Volumn 93, Issue 4, 2001, Pages 549-555

  Griffioen, Marieke ^a   Borghi, Martina ^a   Schrier, Peter I ^a   Osanto, Susanne ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blood; Human; Melanoma; MHC; T lymphocytes

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 2; MONOPHENOL MONOOXYGENASE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; HLA SYSTEM; HUMAN; HUMAN CELL; INFLUENZA; MELANOMA CELL; PEPTIDE ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; T LYMPHOCYTE ACTIVATION;

ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CHROMIUM RADIOISOTOPES; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; VIRAL MATRIX PROTEINS;

EID: 0035882548     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1361     Document Type: Article

References (42)

1. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
2. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
3. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
4. Expression of MAGE genes in primary and metastatic cutaneous melanoma
5. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
6. Sequence and expression pattern of the human MAGE2 gene
7. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
8. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
9. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
10. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
11. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes
12. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
13. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
14. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
15. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
16. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
17. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
18. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
19. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
20. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
21. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
22. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
23. + memory T cells
24. Interleukin-2 induced melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1
25. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A21-restricted anti-melanoma CTL line
26. The minimum peptide epitope from the influenza virus matrix protein extra and intracellular loading of HLA-A2
27. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
28. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
29. HLA A21-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2
30. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
31. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product
32. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids
33. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens
34. Conserved CTL epitopes within EBV latent membrane protein 2: A potential target for CTL-based tumor therapy
35. Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment
36. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients
37. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay
38. Preventing abnormalities in signal transduction of T cells in cancer: The promise of cytokine gene therapy
39. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence of in vivo priming by tumor cells
40. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A21-binding melanoma and viral peptide antigens
41. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
42. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals